Vanderbilt University Medical Center

Displaying 1 - 10 of 19


Understanding the molecules and brain circuits recruited by stressful experience

Stressful experiences can lead to adaptive or detrimental behaviors. Understanding how stress can affect our brains can help understand basic brain function and is also essential to discerning causes and treatments for some diseases. A group of researchers led by Jeffrey Conn, professor of pharmacology at Vanderbilt, explored how specific types of neurons within the prefrontal cortex, the brain area involved in decision-making, mood, and motivation, responded to acute stress in models. They found that one type of inhibitory neuron was persistently activated after acute stress, and this research implicated a receptor that has been targeted by the Warren Center for Neuroscience Drug Discovery (WCNDD) for drug development.


Using a mapping technique to reassess prior Alzheimer’s studies finds ‘powerful,’ improved reproducibility

A neural mapping approach that pegs results from more than two dozen previous Alzheimer’s studies found that reproducibility improves when trying to isolate symptoms to a brain network rather than a single area of the brain.


Low health literacy associated with early death for cardiovascular patients

Patients hospitalized with a cardiovascular event are more likely to die within one year if they have low health literacy, according to a Vanderbilt University Medical Center study released this week in Mayo Clinic Proceedings.


VUMC team devises ‘novel’ idea to help improve hypertension education

Reading a comic book may improve the health of hypertension patients, or at least that’s the goal of a new study at Vanderbilt University Medical Center.


Study reveals safety signal from genes that mimic drugs

Prospective mothers taking a new class of cholesterol-lowering drugs might incur higher risk of spina bifida in their future children, according to a study published in the journal Drug Safety by researchers at Vanderbilt University Medical Center.

The first two drugs in the new class, alirocumab and evolocumab, were approved by the Food and Drug Administration in 2015. They’re taken by patients who don’t respond well to first-line therapy.